Earliest stage treatment of actinic keratosis with imiquimod 3.75% cream: Two case reports—Perspective for non melanoma skin cancer prevention
Citations Over TimeTop 25% of 2020 papers
Abstract
Imiquimod 3.75% cream is licensed for the treatment of actinic keratosis (AK). Two case reports on the treatment of facial UV-exposed skin shall open the discussion if subclinical AKs can be detected by the use of imiquimod cream in UV-exposed areas even if no lesions can be found clinically. A 87-year old female showing small scaly AK lesions on her right cheek was treated with imiquimod 3.75% cream. A 59-year old female without obvious clinical signs of UV-damage on the face experimentally applied imiquimod 3.75% cream twice daily on the entire face for 2 weeks. In the 87-year old, inflammatory reaction developed from day 3 onward and showed field cancerization, the lesions healed without scarring. In the 59-year old at the end of the treatment phase, distinct signs of inflammation appeared, then taking 2 weeks for healing without sequalae. These results open the discussion if the use of imiquimod 3.75% cream could be recommended preventively in UV-exposed skin areas to obviate a later development of AKs/squamous cell carcinoma/nonmelanoma skin cancer.
Related Papers
- → Solar keratoses: Photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies(2013)29 cited
- → A comparison of invasive squamous cell carcinoma greater than 1 year after treatment with 5-fluorouracil, imiquimod, or photodynamic therapy with aminolevulinic acid(2022)11 cited
- → The Overall Number of Actinic Keratosis Lesions Is Not Predictable by the Number of Visible Lesions: Consequences for Field-Directed Therapies(2021)8 cited
- → Comparative study of imiquimod 3.75% vs. photodynamic therapy for actinic keratosis of the scalp(2021)7 cited
- → Efficacy of topical imiquimod 3.75% in the treatment of actinic keratosis of the scalp in immunosuppressed patients: our case series(2019)4 cited